Clinical Trial Update: RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of RAD001 (everolimus) in metastatic, hormone-refractory prostate cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Afinitor (everolimus)

Snippet

Sponsor: Daniel George, MD | Conditions: Hormone Refractory Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-02-07